- Home
- LIXT vs TOVX Comparison
LIXT vs TOVX Comparison
Compare LIXT & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- TOVX
- Stock Information
- Founded
- LIXT 2005
- TOVX 2001
- Country
- LIXT United States
- TOVX United States
- Employees
- LIXT N/A
- TOVX N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- TOVX Health Care
- Exchange
- LIXT Nasdaq
- TOVX Nasdaq
- Market Cap
- LIXT 4.1M
- TOVX 4.0M
- IPO Year
- LIXT N/A
- TOVX 2006
- Fundamental
- Price
- LIXT $1.24
- TOVX $1.42
- Analyst Decision
- LIXT
- TOVX Strong Buy
- Analyst Count
- LIXT 0
- TOVX 1
- Target Price
- LIXT N/A
- TOVX $6.00
- AVG Volume (30 Days)
- LIXT 8.5K
- TOVX 21.6K
- Earning Date
- LIXT 05-08-2025
- TOVX 05-06-2025
- Dividend Yield
- LIXT N/A
- TOVX N/A
- EPS Growth
- LIXT N/A
- TOVX N/A
- EPS
- LIXT N/A
- TOVX N/A
- Revenue
- LIXT N/A
- TOVX N/A
- Revenue This Year
- LIXT N/A
- TOVX N/A
- Revenue Next Year
- LIXT N/A
- TOVX N/A
- P/E Ratio
- LIXT N/A
- TOVX N/A
- Revenue Growth
- LIXT N/A
- TOVX N/A
- 52 Week Low
- LIXT $1.02
- TOVX $0.96
- 52 Week High
- LIXT $3.50
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- LIXT 50.56
- TOVX 60.34
- Support Level
- LIXT $1.10
- TOVX $1.28
- Resistance Level
- LIXT $1.35
- TOVX $1.45
- Average True Range (ATR)
- LIXT 0.11
- TOVX 0.12
- MACD
- LIXT 0.02
- TOVX 0.03
- Stochastic Oscillator
- LIXT 62.40
- TOVX 92.31
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.